Progyny reported an 8.8% increase in revenue, reaching $304.1 million, driven by growth in clients and covered lives. The company achieved record quarterly Adjusted EBITDA of $54.5 million, a 15% increase year-over-year. Net income rose to $16.5 million, or $0.17 per diluted share.
Revenue increased by 8.8% to $304.1 million compared to Q2 2023.
Fertility benefit services revenue grew by 12% to $193.6 million.
Adjusted EBITDA increased by 15% to $54.5 million, with an Adjusted EBITDA margin of 17.9%.
The Board authorized an additional $100 million share repurchase program.
The Company is revising its expectations for the second half of the year to reflect a lesser-than-historical rate of increase in revenue per utilizing member given the variation we're presently seeing.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance